Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells $86,071.45 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALVGet Free Report) CEO Benjamin L. Palleiko sold 7,465 shares of the firm’s stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $11.53, for a total transaction of $86,071.45. Following the completion of the transaction, the chief executive officer now directly owns 224,547 shares of the company’s stock, valued at approximately $2,589,026.91. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ:KALV opened at $12.35 on Thursday. The company’s fifty day moving average price is $11.66 and its 200 day moving average price is $12.12. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.21 and a 12 month high of $16.88. The firm has a market capitalization of $521.05 million, a P/E ratio of -3.92 and a beta of 0.90.

KalVista Pharmaceuticals (NASDAQ:KALVGet Free Report) last announced its quarterly earnings results on Monday, March 11th. The specialty pharmaceutical company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.09). On average, sell-side analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.08 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Quantbot Technologies LP acquired a new position in KalVista Pharmaceuticals in the third quarter valued at $31,000. Tower Research Capital LLC TRC increased its stake in shares of KalVista Pharmaceuticals by 28.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,482 shares of the specialty pharmaceutical company’s stock worth $43,000 after acquiring an additional 768 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of KalVista Pharmaceuticals during the fourth quarter worth about $49,000. AJOVista LLC acquired a new position in shares of KalVista Pharmaceuticals during the fourth quarter worth about $60,000. Finally, EntryPoint Capital LLC acquired a new position in shares of KalVista Pharmaceuticals during the first quarter worth about $92,000.

Wall Street Analysts Forecast Growth

Several brokerages have commented on KALV. Needham & Company LLC reissued a “buy” rating and issued a $35.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday, May 1st. HC Wainwright decreased their price target on shares of KalVista Pharmaceuticals from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, May 3rd.

View Our Latest Research Report on KalVista Pharmaceuticals

About KalVista Pharmaceuticals

(Get Free Report)

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured Stories

Insider Buying and Selling by Quarter for KalVista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.